Toxoid Vaccine Market
Global Toxoid Vaccine Market Size, Share & Trends Analysis Report, By Type (Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (Dtap), Diphtheria and Tetanus (DT)), By End-User (Hospitals and Clinics, Government Organization, and Others) Forecast (2021-2027)
The global toxoid vaccine market is expected to grow at a significant CAGR during the forecast period (2021-2027). The key companies across the globe are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in March 2020, In December 2019, Panacea Biotec, received an award worth $24.3 million from U. N nations (UNICEF and PAHO) for its supply of its WHO prequalified Pentavalent Vaccine. The vaccine protects children from Diphtheria, Tetanus, Pertussis, hepatitis B, and invasive infections caused by Haemophilus Influenza Type b.
Apart from this, in May 2021, GlaxoSmithKline and Samsung partnered to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. The agreement will supplement GSK's existing manufacturing network. Moreover, in April 2021, AstraZeneca proposed acquisition of Alexion Pharmaceuticals, Inc received US Federal Trade Commercial clearance. In addition, in June 2021, Merck acquired the spinoff of Organon & Co. Merck. The acquisition will allow Merck to create two patient-focused companies with enhanced strategies, operational focus, and improved financial profiles. In October 2018, Emergent Biosolutions Inc. acquired PaxVax to expand its portfolio of marketed and pipeline products, expand its manufacturing capabilities and strengthen its presence in the market.
The factor contributing to the growth of the market is the rising prevalence of tetanus. According to the Center for disease control and prevention, 38,000 people died from tetanus in 2017, across the globe, and around half (49%) were younger than five years old. Additionally, the vaccine against tetanus allowed progress in controlling the disease. 89% reduction in tetanus cases and deaths resulted since 1990. Thus, the usefulness of vaccines is contributing to the growth of the market.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Pfizer Inc., Merck KGaA, and GlaxoSmithKline PLC, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Toxoid Vaccine Market Report Segmentation
By Type
• Monovalent Tetanus Toxoid (TT)
• Diphtheria, Tetanus, and Pertussis (DTaP)
• Diphtheria and Tetanus (DT)
By End-User
• Hospitals and Clinics
• Government Organizations
• Others
Global Toxoid Vaccine Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Rest of the World
1. GLOBAL TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
2. GLOBAL TOXOID VACCINE FOR TETANUS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL TOXOID VACCINE FOR DIPHTHERIA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL TOXOID VACCINE FOR PERTUSSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COMPOSITION, 2020-2027 ($ MILLION)
6. GLOBAL MONOVALENT TETANUS TOXOID (TT) VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL DIPHTHERIA AND TETANUS (DT) TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL TETANUS AND DIPHTHERIA (TD) TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL TETANUS, DIPHTHERIA, AND PERTUSSIS (TDAP) TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY FORM, 2020-2027 ($ MILLION)
12. GLOBAL QUADRIVALENT TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL PENTAVALENT TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL HEXAVALENT TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
16. GLOBAL TOXOID VACCINE IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL TOXOID VACCINE IN CLINICS (VETERINARY) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL TOXOID VACCINE IN GOVERNMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
20. NORTH AMERICAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
21. NORTH AMERICAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
22. NORTH AMERICAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COMPOSITION, 2020-2027 ($ MILLION)
23. NORTH AMERICAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY FORM, 2020-2027 ($ MILLION)
24. NORTH AMERICAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
25. EUROPEAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
26. EUROPEAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
27. EUROPEAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COMPOSITION, 2020-2027 ($ MILLION)
28. EUROPEAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY FORM, 2020-2027 ($ MILLION)
29. EUROPEAN TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
30. ASIA-PACIFIC TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
31. ASIA-PACIFIC TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
32. ASIA-PACIFIC TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COMPOSITION, 2020-2027 ($ MILLION)
33. ASIA-PACIFIC TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY FORM, 2020-2027 ($ MILLION)
34. ASIA-PACIFIC TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
35. REST OF THE WORLD TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
36. REST OF THE WORLD TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
37. REST OF THE WORLD TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY COMPOSITION, 2020-2027 ($ MILLION)
38. REST OF THE WORLD TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY FORM, 2020-2027 ($ MILLION)
39. REST OF THE WORLD TOXOID VACCINE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL TOXOID VACCINE MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL TOXOID VACCINE MARKET BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL TOXOID VACCINE MARKET, 2021-2027 (%)
4. GLOBAL TOXOID VACCINE MARKET SHARE BY DISEASE, 2020 VS 2027 (%)
5. GLOBAL TOXOID VACCINE FOR TETANUS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
6. GLOBAL TOXOID VACCINE FOR DIPHTHERIA MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
7. GLOBAL TOXOID VACCINE FOR PERTUSSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL TOXOID VACCINE MARKET SHARE BY COMPOSITION, 2020 VS 2027 (%)
9. GLOBAL MONOVALENT TETANUS TOXOID (TT) VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
10. GLOBAL DIPHTHERIA, TETANUS, AND PERTUSSIS (DTAP) TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
11. GLOBAL DIPHTHERIA AND TETANUS (DT) TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
12. GLOBAL TETANUS AND DIPHTHERIA (TD) TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
13. GLOBAL TETANUS, DIPHTHERIA, AND PERTUSSIS (TDAP) TOXOID VACCINE SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
14. GLOBAL TOXOID VACCINE MARKET SHARE BY FORM, 2020 VS 2027 (%)
15. GLOBAL QUADRIVALENT TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
16. GLOBAL PENTAVALENT TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
17. GLOBAL HEXAVALENT TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
18. GLOBAL TOXOID VACCINE MARKET SHARE BY END-USER, 2020 VS 2027 (%)
19. GLOBAL TOXOID VACCINE IN HOSPITALS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
20. GLOBAL TOXOID VACCINE IN CLINICS (VETERINARY) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
21. GLOBAL TOXOID VACCINE IN GOVERNMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
22. GLOBAL TOXOID VACCINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
23. US TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
24. CANADA TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
25. UK TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
26. FRANCE TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
27. GERMANY TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
28. ITALY TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
29. SPAIN TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
30. REST OF EUROPE TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
31. INDIA TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
32. CHINA TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
33. JAPAN TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
34. SOUTH KOREA TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
35. REST OF ASIA-PACIFIC TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
36. REST OF THE WORLD TOXOID VACCINE MARKET SIZE, 2020-2027 ($ MILLION)
